Negative Antidepressant Trial Results See Low Publication Rate, Study Finds
Executive Summary
The vast majority of antidepressant clinical trials viewed by FDA as having negative or questionable results are either not published in medical journals or published in a way that conveys a positive outcome, according to results of a study published in the January 17 issue of the New England Journal of Medicine
You may also be interested in...
FDA Bill Passes; Congress Adds $225 Million To Industry User Fee Burden
Final FDA reform legislation that cleared Congress adds an additional $225 million to industry's user fee tab over five years, but limits penalties that FDA can assess to enforce its new authorities to mandate labeling changes and postmarket studies
Trial Registry Bill Should Request Protocol With Results, FDA’s Temple Says
Any proposal to expand the ClinicalTrials.gov registry that does not require submission of trial protocols "does not do the whole job," FDA Office of Medical Policy Director Robert Temple said at a June 19 session of the Drug Information Association in Atlanta
Forest Settles With Spitzer; Trial Registry Will Focus On Phase III-IV
Forest Labs' settlement agreement with New York Attorney General Eliot Spitzer requires less disclosure of clinical data than an earlier settlement between Spitzer and GlaxoSmithKline